Jaguar Health, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Jaguar entered a commercial licensing agreement with Future Pak (affiliate of privately held Future Pak LLC) effective January 12, 2026, making Future Pak the exclusive U.S. marketer of Mytesi and Canalevia-CA1; Jaguar received $16M upfront + $3M early termination fee + $1.8M holdback (total ~$20.8M in Q1 2026, $1.8M received in Q3 2026). Company reduced outstanding debt by $10.1M in Q3 2026 through extinguishment (exchanging $600K+ of debt for stock). Q3 2026 net loss improved to $5.8M vs. $9.6M in Q3 2025; product revenue fell 81.9% YoY to $551K as Future Pak now retains all U.S. sales. Company plans NDA filing for crofelemer powder for MVID in mid-2027.
Why this rating
Strategic pivot generating ~$20.8M non-dilutive capital (550% of $3.8M market cap) dramatically improves runway; debt reduction material. Near-term revenue collapse to Future Pak offsets gains, but refocus on R&D for rare-disease pipeline is transformational relative to company size.
Tradability signal
NO TRADE
No trade: price $0.41 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.41 ▲ 7.74% | at our read · unknown $0.39 | +10 min · unknown $0.38 ▼ 0.78% | +30 min · unknown $0.40 ▲ 3.06% | +1 hr · unknown $0.38 ▼ 0.93% | +4 hrs · unknown $0.39 ▲ 2.52% |
The stock had already moved -7.18% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.